Bristol-Myers Squibb (BMY) Fair Value & DCF

BMY$63.43+1.11 +1.78%
Drug Manufacturers - GeneralLarge CapValue StockHigh Quality
Compare
Market cap$129.66BEnterprise value$166.45BRevenue (TTM)$50.03BMarket positionTop 25%

Score

61
Neutral
Value
64
Quality
72
Growth
47

Bristol-Myers Squibb Company (BMY) trades at $63.43 on $129.66B of equity value, with a trailing P/E of 14.03. Fair value on Stocklytics blends discounted cash flow and an earnings-based cross-check when the saved model is on file. The price and ratio here are from the live quote.

Bristol-Myers Squibb (BMY) Fair Value & DCF

BMY price $63.43 +1.11 +1.78%

Ticker
BMY
Price
$63.43
Change
+1.11 +1.78%
Market cap
$129.66B
P/E
14.03
Forward P/E
9.84
Dividend yield
3.93%
Beta
0.23
Sector
Healthcare
Industry
Drug Manufacturers - General
Stocklytics score
61
Value
64
Quality
72
Growth
47

Stocklytics score rationale: value 64, quality 72, growth 47.

AI Score 75. Bristol-Myers Squibb has a strong market cap of $127.71 billion and a solid net profit margin of approximately 18.5%, indicating good profitability. However, its high price-to-earnings ratio of about 13.82 and a price-to-book ratio of 5.45 suggest that it may be overvalued relative to its earnings and assets, which could limit upside potential

Summary

Bristol-Myers Squibb Company operates in Healthcare, within the Drug Manufacturers - General industry. Its overall score is 59.

Valuation

The shares have a P/E of 13.8 and a price-to-book ratio of 5.5. The value score is 64.

Quality

The quality score is 67, supported by a net margin of 18.5%. The dividend yield is 4.0%.

Growth

The growth score is 46, indicating growth is the weakest of the reported factor scores.

Risks

Growth is a relative concern given the growth score of 46. The price-to-book ratio of 5.5 may also be relevant when assessing valuation.

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener